Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
- Conditions
- Alzheimer Disease
- Interventions
- Biological: CAD106
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT01023685
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Alpin Research Center, Boulder, Colorado, United States
🇺🇸ATP Clinical Research, Inc., Costa Mesa, California, United States
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1324
- Registration Number
- NCT01005901
- Locations
- 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey
🇰🇷Novartis Investigative site, Seoul, Korea, Republic of
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 932
- Registration Number
- NCT01001572
- Locations
Investigative site in Romainia
Novartis Investigative Site
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Procedure: Sham laser photocoagulationProcedure: Laser photocoagulation
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 396
- Registration Number
- NCT00989989
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇨🇳Novartis Investigational Site, Shanghai, China
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 260
- Registration Number
- NCT00986414
- Locations
- 🇨🇦
Toronto Western Hospital, UHN, Toronto, Canada
🇪🇸Novartis Investigative Site, San Sebastian, Spain
🇦🇺Novartis Investigational Site, Westmead, Australia
To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 183
- Registration Number
- NCT00986882
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
- Conditions
- Influenza
- Interventions
- Biological: MF59-eH1N1_f
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2719
- Registration Number
- NCT00973349
- Locations
- 🇺🇸
Triangle Medical Research Associates, Raleigh, North Carolina, United States
🇺🇸PI Coor Clinical Research, Fairfax, Virginia, United States
🇺🇸Regional Clinical Research, Endwell, New York, United States
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
- Conditions
- Alzheimer Disease
- Interventions
- Biological: CAD106
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 21
- Registration Number
- NCT00956410
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
- Conditions
- InfluenzaSeasonal Influenza
- Interventions
- Biological: Seasonal Influenza Vaccine
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 126
- Registration Number
- NCT00956449
- Locations
- 🇬🇧
The Health Centre, Suffolk, United Kingdom
Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
- Conditions
- Seasonal Influenza
- Interventions
- Biological: Seasonal Influenza Vaccine (MF59C.1)
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00956761
- Locations
- 🇮🇹
Site 2: Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37, Lanciano, Italy
🇮🇹Site 3: Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48, Pianiga, Italy